Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month

• Published in: Clinical endocrinology (Oxford) 2022-07, Vol.97 (1), p.52-63
• Main Authors: Benderradji, Hamza, Vernotte, Elise, Soto Ares, Gustave, Woillez, Jean Philippe, Jannin, Arnaud, Perbet, Romain, Karnoub, Mélodie‐Anne, Soudan, Benoît, Assaker, Richard, Buée, Luc, Prevot, Vincent, Maurage, Claude‐Alain, Pigny, Pascal, Vantyghem, Marie‐Christine, Merlen, Emilie, Cortet, Christine
• Format: Article
• Language: English
• Subjects: acromegaly; first‐generation somatostatin analogues; lanreotide; MRI; optic chiasm compression; treatment response; visual field defects
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1111/cen.14748

Introduction Few studies have attempted to evaluate the early efficacy of first‐generation somatostatin analogues in somatotroph macroadenomas. Objective To investigate the short‐term efficacy of primary therapy with lanreotide 120 mg at 1 and 3 months on tumour shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly. Design and Patients This single‐centre retrospective study included 21 patients with de novo acromegaly resulting from pituitary macroadenoma, with optic chiasm compression (Grade ≤ 2) and/or cavernous sinus invasion, treated with a monthly injection of lanreotide 120 mg. Clinical, hormonal, ophthalmologic and magnetic resonance imaging scan evaluations were conducted after the first and the third months of treatment. Results Tumour volume reduction was more pronounced at 1 month; mean volume change: −31.4 ± 19.5%, p